BCRX Financial Facts
Product sales: 0Interest and other income: 109K
See Full Income Statement
Deferred collaboration expense: 98K
Other assets: 2.19M
See Full Balance Sheet
BioCryst Pharmaceuticals, Inc. (BCRX) Earnings
|
Expand Research on BCRX
| Next EPS Date | 8/4/26 *Est. | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +1,105.0% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | +6.6% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
4/30/26  |
Q126 | N/A | $0.06 | N/A | N/A | $151.66M | N/A | N/A | N/A | ||
| 2/26/26 | Q425 | $1.12 | $0.04 | +$1.08 | $406.55M | $150.06M | N/A |  | | Details | |
| 11/3/25 | Q325 | $0.16 | $0.05 | +$0.11 | $159.1M | $162.97M | = | | | Details | |
| 8/4/25 | Q225 | $0.15 | $0.01 | +$0.14 | $163.35M | $149.82M | = | | | Details | |
| 5/5/25 | Q125 | $0.00 | -$0.07 | +$0.07 | $134.2M | $127.91M | = | | | Details | |
| 2/24/25 | Q424 | -$0.13 | -$0.07 | -$0.06 | $131.53M | $127.17M | = | | | Details | |
| 11/4/24 | Q324 | -$0.07 | -$0.07 | $0.00 | $116.3M | $113.99M | = | | | Details | |
| 8/5/24 | Q224 | -$0.06 | -$0.17 | +$0.11 | $109.33M | $98.3M | = | | | Details |
